Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Advanced Pharmaceutical Bulletin
ISSN: 2228-5881      eISSN: 2251-7308  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar
PMC(2)


Article History
Submitted: 04 Jun 2014
Revised: 23 Aug 2014
First published online: 25 Aug 2014

Article Access Statistics
Abstract Page Views: 379
PDF Downloads: 156
Full Text Views: 0

Adv Pharm Bull. 2014;4(5):471-477 doi: 10.5681/apb.2014.070
PMID:25364665        PMCID:PMC4213788

Effect of Beta Glucan on Quality of Life in Women With Breast Cancer Undergoing Chemotherapy: A Randomized Double-Blind Placebo-Controlled Clinical Trial

Original Research

Alireza Ostadrahimi 1, Ali Esfahani 2, Mohammad Asghari Jafarabadi 3, Jamal Eivazi Ziaei 2, Aliakbar Movassaghpourakbari 2, Nazila Farrin 4 *

1 Nutrition Research Center, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Hematology and Oncology Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Tabriz Health Services Management Research Center, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Studentʾsʾ Research Committee, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.



Abstract
Purpose: Breast cancer is the most common female malignancy in the world. Beta glucan may improve quality of life in cancer patients receiving chemotherapy. The aim of this trial was to determine the effect of Beta glucan on quality of life in women with breast cancer undergoing chemotherapy. Methods: This study was conducted on 30 women with breast carcinoma. The eligible participants were randomly assigned to intervention (n=15) or placebo (n=15) groups using a block randomization procedure. Patients in the intervention group received two 10-mg capsules of soluble 1–3, 1–6, D-beta glucan daily and the placebo group received placebo for 21 days, in an interval between two courses of chemotherapy. Health - related quality of life (HRQL) was evaluated using the EORTC Quality of Life Questionnaire version.3.0 (EORTC QLQ-C30) at the beginning and end of the study. Results: At the end of the study, the Global health status /QoL score for the Beta glucan group was significantly increased (P=0.023), but the difference between the two groups was not significant. After intervention, the Functional scales score showed no significant change (P=0.099) between the two groups or within the groups. At the end of the study, the Symptom scales\items score was decreased significantly in Beta glucan group comparing the placebo group (P=0.048), as well as after adjusting for baseline score. The Symptom scales\items score’s change was significant (P=0.012) within the Beta glucan group, compared with the baseline score. Conclusion: The findings suggest that Beta glucan may be useful as a complementary or adjuvant therapy for improving quality of life in breast cancer patients in combination with cancer therapies.





Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Ostadrahimi A
Articles by Esfahani A
Articles by Asghari Jafarabadi M
Articles by Eivazi Ziaei J
Articles by Movassaghpourakbari A
Articles by Farrin N

PubMed
Articles by Ostadrahimi A
Articles by Esfahani A
Articles by Asghari Jafarabadi M
Articles by Eivazi Ziaei J
Articles by Movassaghpourakbari A
Articles by Farrin N

Similar articles in PubMed

Share this article!

Press Manuscript Online. Powered by MAADRAYAN